December 2011

Contents

Editorial

• Volume 12 Number 11/12 November/December 2011

Conference reports

• 13th European AIDS Conference (EACS), Belgrade, Serbia, 12-15 October 2011

• European guidelines (EACS) – 2011 update

• Raltegravir achieves superiority over efavirenz after four years

• Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients

• Ritonavir levels reduced with high fat meal

• Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates

• 2nd International Workshop on HIV and Ageing, Baltimore, Maryland, 27-28 October 2011

• Statin blocks negative impact of PIs on bone formation in vitro

• HIV linked to frailty in middle-aged IDUs, especially with poor HIV control

• 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, 17-20 September 2011

• Monitoring kidney function change with cobicistat

• Intracellular raltegravir concentrations better with twice-daily than once-daily dosing

Antiretrovirals

• Rilpivirine (Edurant) and rilpivirine/FTC/tenofovir FDC (Eviplera) approved in Europe

• FDA updates US label for darunavir for serious rash

• FDA updates US label for raltegravir due to serious rash

• Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily

• Switching to 50mg ritonavir dose for selected protease inhibitors

• New formulations, acquisitions and company announcements

• US guidelines (DHHS) update recommendations for first-line combinations (October 2011)

Treatment access

• Global Fund cancels Round 11 and introduces new rules for grant renewals

• FDA approval of generic ARVs

• We need the Patent Pool to work

Paediatric care

• Efavirenz under-dosing in children

• Treatment response and duration of first line treatment in European infants

Coinfections and complications

• US guidelines for management of older people living with HIV (2011)

• New studies on HIV and the diseases of ageing

• Risk of cataract surgery higher in HIV positive compared to HIV negative people

• CD4 count <200 independently associated with 5-fold increased risk of fracture

HIV prevention and transmission

• International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy

• UK Health Protection Agency (HPA) recommends universal HIV testing in the high incidence regions of the UK

Cure-related research

• Cure research: report from research workshop

Basic science and immunology

• Exercise as immune-based therapy

• Mapping the long genetic road to broadly neutralising antibodies

• Monkey viral reservoir study goes for gold

• Immune pressure on HIV

• Lymphocyte production capacity in HIV: links to immune activation & immune reconstitution on ART

Book and film reviews

• We Were Here

Other news

• Iranian doctors now freed

• New York court rejects AIDS denialist case against leading HIV community activist and journalist

• UK ban on HIV-positive doctors and dentists set to be overturned

On the web

• Free full text online articles

PDFs

• Volume 12 Number 11/12 November/December 2011 PDF